<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04257786</url>
  </required_header>
  <id_info>
    <org_study_id>epithelial ovarian cancer</org_study_id>
    <nct_id>NCT04257786</nct_id>
  </id_info>
  <brief_title>Primary Cyto-reductive Surgery Vs Neo-adjuvant Chemotherapy (NAC) in Epithelial Ovarian Cancer</brief_title>
  <acronym>ovarian cancer</acronym>
  <official_title>Primary Cyto-reductive Surgery Vs Neo-adjuvant Chemotherapy (NAC) Followed by Surgery in Patients With Advanced Primary Epithelial Ovarian Cancer: A Pilot Randomized Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Assessment of efficacy of primary cyto-reductive surgery in patients with advanced primary
      epithelial ovarian cancer in Comparison to patients receiving neo-adjuvant chemotherapy (NAC)
      followed by surgery in complete excision of the tumor reaching R0 without significant
      morbidity.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">March 1, 2020</start_date>
  <completion_date type="Anticipated">April 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of patient where complete resection of the tumor can be achieved</measure>
    <time_frame>3 month postoperative</time_frame>
    <description>complete resection of the tumor</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Advanced Cancer</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1ry surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Neoadjuvant Chemotherapy followed by surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>1ry cyto-reductive surgery</intervention_name>
    <description>1ry surgery then chemotherapy</description>
    <arm_group_label>Group 1</arm_group_label>
    <other_name>1ry surgery</other_name>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Neoadjuvant chemotherapy followed by surgery</intervention_name>
    <description>chemotherapy then surgery</description>
    <arm_group_label>Group 2</arm_group_label>
    <other_name>Neoadjuvant chemotherapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Female patients diagnosed with epithelial ovarian cancer (By histopathology)

        Age ≥ 18 years old

        Advanced defined as (stage 2D or more ) by surgical staging.

        Performance status (PS) according to Eastern Cooperative Oncology Group (ECOG) ≤ 2

        Chemotherapy naïve

        Informed consent

        Exclusion Criteria:

        Patients previously received chemotherapy or radiotherapy to any part of the abdomen or
        pelvis.

        Patients with uncontrolled infection.

        Patients with active bleeding or conditions associated with high risk of bleeding.

        contraindications for surgery

        contraindications To chemotherapy - bevacizumab
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ali H Ali Sayed, M.Sc</last_name>
    <phone>02 01061830890</phone>
    <email>lolf372@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ali hussien Ali sayed</name>
      <address>
        <city>Assiut</city>
        <zip>71111</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 4, 2020</study_first_submitted>
  <study_first_submitted_qc>February 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 6, 2020</study_first_posted>
  <last_update_submitted>February 4, 2020</last_update_submitted>
  <last_update_submitted_qc>February 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Ali hussien ali sayed</investigator_full_name>
    <investigator_title>Specialist</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

